NCT06708949View on ClinicalTrials.gov

A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)

PHASE2RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 20, 2025

Primary Completion Date

December 15, 2026

Study Completion Date

December 15, 2028

Conditions
Renal Cell Carcinoma, Clear Cell
Interventions
DRUG

Drugs Nivolumab

Given by IV Infusion

DRUG

Ipilimumab

Given by IV Infusion

DRUG

BMS-986213 (Relatlimab-Nivolumab FDC)

Given by IV Infusion

Trial Locations (2)

75390

RECRUITING

University of Texas Southwestern Medical Center, Dallas

77030

RECRUITING

The University of Texas M. D. Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT06708949 - A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC) | Biotech Hunter | Biotech Hunter